Chau Q. Khuong has been a member of our Board of Directors since 2016.  Mr. Khuong is a seasoned healthcare investor and entrepreneur with over twenty five years experience investing in private and public biotechnology and medical device companies.  He currently manages investments from CJNV BioVentures, a life science focused entity he founded in 2021 to provide capital solutions and strategic advisory to life science entrepreneurs, particularly in the formative phase of their company creation journey.

From 2003 to 2021 he worked at OrbiMed Advisors, a global healthcare-dedicated investment firm with $15 billion AUM,  where he was Partner and member of the investment committees directing capital deployment from OrbiMed’s flagship venture capital funds.  He has been an active lead investor in healthcare innovation across all company stages and therapeutic areas including oncology, infectious disease, ophthalmology, liver disease, and genetic medicines.  Mr. Khuong currently serves or has served as a Board Director at numerous public and private companies including Arius Research (acquired by Roche), Bellus Health (acquired by GSK), Fusion Pharma (acquired by AstraZeneca), Glaukos Medical (NYSE: GKOS), Intellia (NASDAQ: NTLA), Inspire Medsystems (NYSE: INSP), Intercept Pharma (acquired by Alphasigma), OnCusp Therapeutics, Rempex (acquired by Medicines Company), Restora Medical, and ReViral (acquired by Pfizer).

Prior to OrbiMed, Mr. Khuong was an early employee at Veritas Medicine, a startup company that innovated clinical trials patient recruitment with an AI driven matching algorithm.  He also conducted basic science research in transplantation immunology at Massachusetts General Hospital and at Yale School of Medicine.  He received a B.S. (Molecular Biology) and an MPH (Infectious Disease Epidemiology) both from Yale University.